Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 18;4(4):E623-E633.
doi: 10.9778/cmajo.20150052. eCollection 2016 Oct-Dec.

Cost-effectiveness of palivizumab compared to no prophylaxis in term infants residing in the Canadian Arctic

Anna Banerji  1 , Kaspar Ng  1 , Theo J Moraes  1 , Vladimir Panzov  1 , Joan Robinson  1 , Bonita E Lee  1
Affiliations

Cost-effectiveness of palivizumab compared to no prophylaxis in term infants residing in the Canadian Arctic

Anna Banerji et al. CMAJ Open. .

Abstract

Background: Hospital admissions for respiratory syncytial virus infection result in large health expenditures for Inuit infants. Palivizumab has been shown to be highly effective in reducing such admissions in preterm Inuit infants. We performed a cost-effectiveness analysis estimating the incremental cost-effectiveness ratio (ICER) for palivizumab prophylaxis per admission related to respiratory syncytial virus avoided in healthy term infants across the Canadian Arctic.

Methods: We compared universal palivizumab prophylaxis in term infants less than 6 months of age to no prophylaxis in 8 Arctic regions: the Northwest Territories, Nunavut, Nunavut without Iqaluit, the 3 subregions of Nunavut (Kitikmeot, Kivalliq and Qikiqtaaluk), the Qikiqtaaluk Region without Iqaluit, and Nunavik (northern Quebec). Costs were acquired from the territorial governments, hospitals and contracted agencies. The perspective is that of the public payer, with a 6-month timeline. In scenario A, universal prophylaxis was provided until the end of the respiratory syncytial virus season, and in scenario B, infants received prophylaxis until 5 months of age. The ICERs of scenario A were compared with those of scenario B.

Results: Under scenario A, the cost per admission avoided was as high as $546 115 in the Northwest Territories, compared with a cost savings of $36 145 in the Kitikmeot Region. Under scenario B, the ICER showed cost savings of $48 549 in the Kitikmeot Region and $2731 in the Kivalliq Region, with low ICERs in Nunavik of $15 601.

Interpretation: Considerable cost savings were found for the Kitikmeot Region with universal palivizumab prophylaxis in term infants with both scenarios, whereas cost savings were found for the Kivalliq Region with scenario B. Stopping prophylaxis at 5 months of age was a more cost-effective strategy in all regions except the Kitikmeot Region. Nunavik had low ICERs, and prophylaxis should be considered for this region.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Joan Robinson received grants from Abbott and Medimmune during the conduct of the study.This article has been peer reviewed.

Figures

Figure 1
Figure 1
Incremental cost-effectiveness ratio for scenario A, palivizumab prophylaxis for healthy term infants across the Canadian Arctic compared with no prophylaxis for infants less than 6 months of age at or during the 2009 respiratory syncytial virus (RSV) season (Jan. 1-June 30). †Prophylaxis up to 5 months of age provides 6 months of protection. ‡Scenario C, sensitivity analysis using 78% risk reduction.
Figure 2
Figure 2
Incremental cost-effectiveness ratio for scenario B, palivizumab prophylaxis compared with no prophylaxis for healthy term infants across the Canadian Arctic up to 5 months of age. *Population at risk is fluid, with equal number meeting inclusion criteria (through birth) as exclusion criteria. †Estimated risk reduction 96%. ‡Prophylaxis up to 5 months of age provides 6 months of protection. RSV = respiratory syncytial virus.
See this image and copyright information in PMC

Comment in

References

    1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–55. - PMC - PubMed
    1. Banerji A. High rates of hospitalisation for bronchiolitis in Inuit children on Baffin Island. Int J Circumpolar Health. 2001;60:375–9. - PubMed
    1. Young M, Kandola K, Mitchell R, et al. Hospital admission rates for lower respiratory tract infections in infants in the Northwest Territories and the Kitikmeot region of Nunavut between 2000 and 2004. Paediatr Child Health. 2007;12:563–6. - PMC - PubMed
    1. Carson JB, Postl BD, Spady D, et al. Lower respiratory tract infections among Canadian Inuit Children. Int J Circumpolar Health. 1984;84:226–8.
    1. Banerji A, Greenberg D, White LF, et al. Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children: a case-control study. Pediatr Infect Dis J. 2009;28:697–701. - PubMed

LinkOut - more resources